Open AccessNeuropathy experienced by colorectal cancer patients receiving oxaliplatin: A qualitative study to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale
Author(s) -
Karen Kaiser,
Madison Lyleroehr,
Sara Shaunfield,
Leilani Lacson,
María Eugenia Jiménez Corona,
Sheetal Mehta Kircher,
Malin Nittve,
David Cella
Publication year - 2020
Publication title -
world journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 26
ISSN - 1948-5204
DOI - 10.4251/wjgo.v12.i2.205
Subject(s) - medicine , gynecologic oncology , oxaliplatin , quality of life (healthcare) , chemotherapy induced peripheral neuropathy , peripheral neuropathy , colorectal cancer , physical therapy , oncology , cancer , nursing , endocrinology , diabetes mellitus
Although oxaliplatin is widely established as a standard treatment in colorectal cancer (CRC), oxaliplatin-induced neuropathy has emerged as a prominent dose-limiting side effect associated with quality of life decrements. Ongoing monitoring and management of neuropathy is important for CRC patient quality of life and adherence to treatment. Therefore, a validated self-reported measure of neuropathy would aid in the management and assessment of oxaliplatin-induced neuropathy in clinical practice and research. We sought to evaluate the content validity of the 13-item Functional Assessment of Cancer Therapy/Gynecologic Oncology Group- Neurotoxicity subscale (FACT/GOG-Ntx) for CRC patients receiving oxaliplatin.